Related by context. All words. (Click for frequent words.) 68 AASLD 67 Clinical Oncology 67 Clinical Oncology ASCO 66 ASCO Annual Meeting 66 AACR 63 ASH Annual Meeting 63 AACR NCI EORTC 62 Clinical Oncologists 62 Clinical Oncology Annual Meeting 61 ESMO 61 ASCO GI 61 ICAAC 61 SABCS 61 EORTC NCI AACR 60 Hematology ASH 60 Genitourinary Cancers Symposium 60 Clinical Oncology ASCO Annual 60 EASL 58 AACR #nd Annual Meeting 58 EuroPCR 58 Gastrointestinal Cancers Symposium 58 Hematology 58 ACR ARHP 58 Cancers Symposium 58 nd Annual Meeting 57 Digestive Disease Week DDW 57 ADA Scientific Sessions 57 Digestive Disease Week 57 ARVO 56 AHA Scientific Sessions 56 Hematology ASH Annual Meeting 56 ICAAC IDSA 56 American Urological Association 56 Society CTOS 56 Hematology Annual Meeting 56 AACR #st Annual Meeting 56 ASCO GU 56 American Thoracic Society 55 CTRC AACR San Antonio 55 Connective Tissue Oncology 55 ECTRIMS 55 ISPOR 55 Scientific Session 55 Prostate Cancer Symposium 55 ASCO Genitourinary Cancers Symposium 55 San Antonio Breast Cancer 55 AACR San Antonio 55 PROSTVAC TM 54 CROI 54 Late Breaker 54 Malignant Mesothelioma 54 Transcatheter Cardiovascular Therapeutics TCT 54 Hematology Meeting 54 AACR Annual Meeting 54 Rheumatology ACR Annual 54 Digestive Diseases Week 54 axitinib 54 AAPM 54 Therapeutic Radiology 54 BCIRG 54 picoplatin 54 AUA Annual Meeting 54 #th Annual Interscience 53 Scientific Sessions 53 EORTC 53 www.asco.org 53 enzastaurin 53 EASD 53 ASA# 53 Chicago Multidisciplinary Symposium 53 UEGW 53 Therapeutic Radiation 52 ASBMR 52 Breast Cancer Symposium 52 ORAL Sync 52 st Annual Meeting 52 EULAR 52 AACR NCI EORTC Molecular 52 Cardiology ACC 52 RTOG 52 Radiation Oncology ASTRO 52 EORTC NCI 52 ASCO Breast Cancer 52 ECCMID 52 ECCO ESMO 52 EORTC NCI AACR Symposium 52 AVADO 52 AASLD Meeting 52 Transcatheter Cardiovascular Therapeutics 52 Pharmacoeconomics 52 ISHLT 52 Oral Presentations 52 perifosine 52 Medical Oncology ESMO 52 Endocrine Society ENDO 52 ASGT 52 Biological Therapy 52 Neurology AAN 51 HFSA 51 Interventions SCAI 51 Antimicrobial Agents 51 CALGB 51 ixabepilone 51 IASLC 51 Hypertension ASH 51 MOZOBIL 51 League Against Rheumatism 51 Oncology ASTRO 51 VEITHsymposium 51 ToGA 51 Outcomes Research ISPOR 51 Dr. Pingpank 51 SPIRIT IV 51 website www.asco.org 51 ASCO abstract 51 BIOCOM Investor Conference 51 Alzheimer Disease ICAD 50 Dr. Yatscoff 50 International Myeloma Workshop 50 ICAD 50 Keystone Symposia 50 Endovascular Therapy ISET 50 Nephrology Renal Week 50 HORIZONS AMI 50 #nd Annual Meeting 50 iSBTc 50 AAN Annual Meeting 50 Celgene Revlimid 50 ASTRO Annual Meeting 50 viral kinetic 50 Brentuximab Vedotin SGN 50 HCV Protease Inhibitor 50 Annual Scientific Sessions 50 Interventional Radiology SIR 50 Heart Failure Society 50 GRN#L 50 ipilimumab 50 AP# [003] 50 abstracts 50 Carfilzomib 50 XL# [003] 50 Pediatric Academic Societies PAS 50 cabozantinib 50 SUCCEED trial 50 RSNA 50 neratinib 50 ESTRO 50 #st Annual Meeting 50 DDW 50 DDW ® 50 ENESTnd 50 NSABP 49 Revlimid 49 Erbitux 49 Cancer iSBTc 49 Gynecological Cancer 49 Breast Cancer Symposium SABCS 49 Thoracic Oncology 49 Pharmaceutical Scientists AAPS 49 sipuleucel T 49 lintuzumab 49 ASH 49 ongoing Phase 1b 49 Rheumatology Annual Meeting 49 Alpharadin 49 CR# vcMMAE 49 PERSEUS 49 Phase #/#a trial 49 Dendreon Provenge 49 Clinical Chemistry AACC 49 Opexa 49 BiTE R 49 Breast Surgeons 49 Scientific Meeting 49 Liver Diseases 49 Breast Surgeons ASBS 49 farletuzumab 49 ganetespib 49 Breaking Clinical Trials 49 pazopanib 49 Poster Discussion 49 YONDELIS 49 metastatic colorectal cancer 49 ePRO 49 ACR ARHP Annual 49 EVEREST II 49 Amrubicin 49 Cardiology 49 Cardiology Scientific Sessions 49 Recurrent Chest Wall 49 preclinical efficacy 49 carfilzomib 49 Spine Arthroplasty Society 49 Neuro Oncology 49 #th Interscience Conference 49 LymphoStat B 49 entitled Synergistic 49 atrasentan 49 Vectibix 49 Arteriosclerosis Thrombosis 48 ACRIN 48 HORIZONS AMI trial 48 Pediatric Academic Societies 48 Cambridge Healthtech Institute 48 NCCN 48 Prostate AdenoCarcinoma Treatment 48 sapacitabine 48 Liver Diseases AASLD 48 randomized discontinuation trial 48 Aplidin 48 ENDEAVOR III 48 Rheumatology Annual 48 oral FTY# 48 KRAS status 48 ZACTIMA 48 T DM1 48 Stem Cell Research ISSCR 48 bevacizumab Avastin 48 Satraplatin 48 Abiraterone 48 CTRC AACR 48 CRLX# 48 Respiratory Society 48 Rheumatology 48 Tanespimycin 48 Microbiology ASM 48 abstracts summarizing 48 Radiation Therapy Oncology 48 Abstract # 48 FDA Oncologic Drugs 48 Breaking Clinical Trial 48 PXD# 48 th Interscience Conference 48 Heart Rhythm 48 assessing T DM1 48 multicenter trials 48 USpella 48 Oncogenex 48 INCB# [001] 48 SWOG 48 Ceflatonin 48 Avastin 48 BRIM2 48 eltrombopag 48 Mineral Research ASBMR 48 Phase Ib II 48 Nexavar sorafenib 48 TASKi2 48 Endocrine Society Annual Meeting 48 MelaFind pivotal 48 Hematology ASH Meeting 48 aflibercept 48 Zarnestra 48 IMGN# 48 Oncologic Drugs Advisory 48 Lung Transplantation 48 cediranib 48 neoadjuvant treatment 48 oral Xeloda 48 FTY# 48 KRN# 48 sunitinib malate 48 Retroviruses 48 SYNTAX trial 48 Cotara 48 depsipeptide 48 AS# amonafide L malate 48 Zybrestat 48 CUSTOM II 48 Cell Biology ASCB 48 glufosfamide 48 Liver Disease AASLD 48 OPAXIO 48 NEJM 48 Randomized Phase III 48 NCCN guidelines 48 cetuximab Erbitux 48 ASHP 48 Interscience Conference 48 Malignant Lymphoma 48 Phase Ib clinical 48 Therapeutics TCT 48 abiraterone 48 pertuzumab 48 #nd EORTC NCI 48 ENMD 48 BRIM3 48 LBH# 48 HuMax EGFr 47 Lung Cancer IASLC 47 ACUITY trial 47 obatoclax 47 Cachexia 47 Combination REOLYSIN R 47 BR.# 47 mRCC 47 AVAX 47 Ambrisentan 47 ASCRS 47 multicenter Phase 47 Quinamed 47 Daniel Junius 47 Symposium SABCS 47 AACR Meeting 47 Phase III ALLEGRO 47 Echocardiography ASE 47 Neuvenge 47 AACR Frontiers 47 Xinlay 47 metastatic renal cell carcinoma 47 Sutent 47 SU# [003] 47 Molecular Targets 47 EOquin TM 47 EXPAREL ™ 47 Clinical Virology Symposium 47 ISTH 47 rALLy trial 47 Phase III psoriasis 47 ANTEGREN 47 Gastroenterology ACG 47 vascular disrupting agent 47 Antisoma 47 Avastin bevacizumab 47 MEDCAC 47 vismodegib 47 CLARITY study 47 Therapeutics TCT scientific 47 CAMMS# 47 teriflunomide 47 Neuropsychopharmacology 47 Annual Transcatheter Cardiovascular 47 oral ridaforolimus 47 TCT 47 PEG SN# 47 Neurology Annual Meeting 47 ASCB 47 Dr. Gulfo 47 trastuzumab DM1 47 seliciclib 47 NO# [002] 47 Endocrine Society #st 47 OXi# 47 SCDM 47 Urology EAU 47 annual Transcatheter Cardiovascular 47 Virulizin ® 47 Cloretazine ® 47 EUROGIN 47 L BLP# 47 ON #.Na 47 TAXUS IV 47 prostate cancer mCRPC 47 Provenge 47 Dacogen injection 47 Epilepsy Society 47 Anesthesiologists ASA 47 ILLUMINATE 47 Antibody Therapeutics 47 Opportunistic Infections CROI 47 boceprevir 47 www.hematology.org 47 HCV SPRINT 47 elesclomol 47 Gynecologic Cancer Society 47 Multiple Myeloma 47 alvespimycin 47 Gastroenterology ACG Annual 47 Canaccord Adams Hepatitis C 47 brentuximab vedotin 47 Pirfenidone 47 LUX Lung 47 Reolysin 47 Clinical Trial Results 47 Cancer Immunotherapy 47 Clinical Therapeutics 47 Kantarjian 47 Targretin 47 Liver EASL 47 ENDEAVOR IV 47 Phase 2b RESTORE CLI 47 randomized Phase III 47 Chronic Lymphocytic Leukemia 47 Ph.D. MD hc 47 clinical trial 47 Abstracts 47 Hedgehog Pathway Inhibitor 47 evaluating REVLIMID 47 Phase III VISTA 47 America HFSA 47 Nasdaq DNDN 46 phase Ib 46 Hematological Malignancies 46 HER2 positive metastatic breast 46 Allovectin 7 ® 46 QOPI 46 AANS 46 Richard Schilsky 46 NCCTG N# 46 BiTE antibody MT# 46 Nexavar 46 denosumab 46 Allovectin 7 46 TAXUS ATLAS 46 Phase #b/#a clinical 46 HuMax CD4 46 trastuzumab DM1 T DM1 46 BIO InvestorForum 46 Cloretazine R 46 NASDAQ CXSP announced 46 Genasense 46 Gastrointestinal Cancer 46 HDAC Inhibitor 46 tanespimycin 46 Dose Escalation 46 Dr. Agarwala 46 ERA EDTA 46 blinatumomab 46 Anesthesiologists Annual Meeting 46 Glufosfamide 46 EFNS 46 sorafenib Nexavar 46 AACR symposium 46 Clinical Oncology Gastrointestinal Cancers 46 AACR EORTC NCI 46 Cardiostim 46 FOLOTYN 46 Clinical Endocrinologists AACE 46 SCAI Annual 46 deforolimus 46 seliciclib CYC# 46 Gynecologic Oncologists 46 NASDAQ CYTK announced 46 Phase 1b 46 antitumor activity 46 ISPE 46 TG MV 46 Retina Specialists 46 AEZS 46 Taxotere ® 46 Cellular Therapy ISCT 46 EACTS 46 anti angiogenic therapy 46 CALGB # [002] 46 Promacta 46 Gene Therapy ASGT 46 Hsp# Inhibitor 46 Revlimid lenalidomide 46 Lysosomal Disease Network 46 ThermoDox R 46 Phase Ib 46 ASHG 46 Experimental Biology EB 46 Gynecologic Oncologists SGO 46 AACR IASLC Joint 46 Tarvacin 46 phase 2a 46 NCCTG 46 Cardiovascular Anesthesiologists 46 TACI Ig 46 Surgical Oncology SSO 46 Cardiology ESC 46 Campath 46 NCIC CTG 46 INCB# [002] 46 Gene Therapy 46 CHEST 46 multicenter randomized Phase 46 LSE ASM 46 hematologists 46 BARI 2D 46 Actemra 46 pancreatic islet cell 46 palifosfamide 46 phase IIb 46 pediatric acute lymphoblastic 46 Telaprevir 46 Phase Ib study 46 SAWC 46 NCCN Guidelines Panel 46 PCK# 46 Solid Tumors 46 iclaprim 45 ASCO Gastrointestinal Cancers Symposium 45 entinostat 45 ESHRE 45 metastatic melanoma 45 NSCLC 45 #rd Annual CTRC 45 ovarian suppression 45 Nasdaq ONXX today 45 Lung Cancer 45 SAEM Annual Meeting 45 Vertex telaprevir 45 CUSTOM III 45 Endocrine Society #nd 45 YONDELIS R 45 Dr. Grekos 45 dose escalation clinical 45 Dr. Von Hoff 45 CLL8 45 standard chemotherapy regimen 45 FDA Advisory Panel 45 phase IIa clinical 45 Clinical Microbiology 45 IMPACT IMmunotherapy 45 Reverset 45 Poniard 45 Bortezomib 45 NEVO RES 45 Chemotherapy ICAAC 45 Aflibercept 45 EuroIntervention 45 Vascular Biology ATVB 45 NEUVENGE 45 Zactima 45 comparing alemtuzumab 45 PTK ZK 45 ExL Pharma 45 darinaparsin ZIO 45 Developmental Therapeutics Immunotherapy 45 ACM SIGCOMM 45 Clinical Oncology ASCO Gastrointestinal 45 Immunotherapeutic 45 Phase III AFFIRM 45 Phase 2a clinical 45 SCD HeFT 45 Tarceva 45 Biophysical Society 45 EULAR Annual 45 Daniel Von Hoff 45 Vandetanib 45 clevidipine 45 Supportive Care 45 GW# [003] 45 Ophthalmology ARVO 45 Romidepsin 45 OneMedForum 45 ProSavin 45 RE LY 45 SIR Spheres 45 trabectedin 45 Gastrointestinal Oncology 45 SMi 45 journal Resuscitation 45 Neuro Oncology SNO 45 Genasense ® 45 Needham Biotechnology 45 Oncology 45 Oral Presentation 45 Nasdaq ENZN 45 Advexin 45 metastatic hormone refractory 45 Targeted Therapies 45 Randomized Comparison 45 Endocrine Society 45 Perifosine 45 phase IIa 45 Pemetrexed 45 APPRAISE 45 Menopause Society NAMS 45 CA4P 45 vidofludimus 45 eyeforpharma 45 Proxinium TM 45 Natalie Compagni Portis 45 ISA# [002] 45 panitumumab 45 Amgen Vectibix 45 Tesmilifene 45 Pharmatech Oncology 45 sunitinib Sutent 45 Castration Resistant Prostate Cancer 45 ASCO Prostate Cancer 45 Nephrology ASN Renal 45 journal Antimicrobial Agents 45 Neuropsychopharmacology ACNP 45 Cell Transplant 45 Phase IIB 45 PreCISe 45 Angiolix 45 DFCI 45 Patient Recruitment 45 RGB # 45 Removab 45 amrubicin 45 oncologists 45 ELSO 45 Sipuleucel T 45 Dr. McHutchison 45 HUPO 45 Clinical Cancer 45 Everolimus 45 Bapineuzumab 45 DASISION 45 evaluating tivozanib 45 Inc. Nasdaq AMLN 45 Anticancer Drugs 45 Neoplasia 45 Clinical Oncology JCO 45 Controlled Release 45 pralatrexate 45 Clavis Pharma 45 phase IIb clinical 45 Surgeons ACS 45 Breast Disease 45 Annual ICAAC 45 Diabetologia 45 Immutep 45 European CanCer Organisation ECCO 45 Pharmacoepidemiology 45 AABB Annual Meeting 45 TTF Therapy 45 IRX 2 45 decitabine 45 vandetanib 45 CARE HF 45 anastrozole Arimidex 45 Neck Cancer 45 Onyx Pharma 45 Tykerb 45 Semafore Pharmaceuticals 45 Hepatocellular Carcinoma HCC 45 ELACYT 45 Gynecologic Oncology Group 45 Rituxan 45 R roscovitine 45 Medicinal Chemistry Letters 45 Velcade 45 Yondelis 45 proteasome inhibitor 45 ADVEXIN 45 HRPC 45 Romiplostim 45 NASDAQ PCYC 45 Molecular Medicine Tri 45 Clinical Trial Data 45 ISSCR 45 HGS ETR1 45 LibiGel Phase III 45 Capsule Endoscopy 45 mg administered orally 45 AOSSM 45 Dr. Scangos 45 MASCC 45 peginesatide 45 Anticancer Drug 45 ICON7 45 Velcade bortezomib 45 Hyphanox 45 Marrow Transplantation 45 Panzem 44 Traficet EN 44 Clinical Oncologists ASCO 44 anti angiogenic agents 44 REOLYSIN ® 44 TRO# 44 satraplatin 44 AGBT 44 pharmacokinetic PK study 44 Temsirolimus 44 dose escalation trial 44 BHIVA 44 Dr. Ayalew Tefferi 44 Liver Meeting 44 brivaracetam 44 ACC.# 44 Hana Biosciences 44 Alimta 44 National Surgical Adjuvant 44 AAN 44 CoFactor 44 Diasome 44 Daclizumab 44 Syndax 44 ROCKET AF 44 PANVAC VF 44 Neurological Surgeons AANS 44 American Psychosomatic Society 44 OncoVEX GM CSF 44 PROTECT II 44 ELCAP 44 Bladder Cancer 44 tolerability profiles 44 placebo controlled clinical 44 AAAAI 44 EndoTAG TM -1 44 TNFerade 44 Treanda 44 ASLMS 44 MDV# 44 Cellular Therapy 44 Hygiene ASTMH 44 Cardiovascular Interventions 44 Sunitinib 44 Canvaxin 44 Cardiovascular Therapeutics 44 satraplatin Phase 44 RESTORE CLI 44 Novartis Zometa 44 INFORMS 44 AIDAC 44 pharmacokinetic pharmacodynamic 44 HFSA Annual 44 Randomized Phase 44 Cancer Research 44 SUTENT ® 44 Gastrointestinal Endoscopy 44 vinca alkaloid 44 Antisoma AS# 44 recurrent GBM 44 ponatinib 44 Prostate Cancer Prevention 44 ImmunoVEX HSV2 44 Headache Society 44 PRECISE 44 Rheumatologists 44 Phase 1b trial 44 Pharmacological Society 44 Onconase 44 ASM Biodefense 44 Printable slides 44 Myeloma 44 HQK 44 Advanced Neuroendocrine Tumors 44 Hematologic Malignancies 44 CUDC 44 IRESSA 44 Antiviral Activity 44 BioProcess International 44 Potent Antiviral Activity 44 PNT# 44 Novartis Gleevec 44 metastatic colorectal 44 imetelstat 44 Defibrotide 44 HyQ 44 Inflammatory Bowel Diseases 44 PIVOT RLS 44 HIMSS 44 Taxotere R 44 ThermoDox ® 44 randomized controlled Phase 44 PARTNER Trial 44 Pluristem Therapeutics 44 BRAF inhibitor 44 ACCORD Lipid 44 Annual Meeting 44 Enzastaurin 44 Dasatinib 44 AAPS Annual Meeting 44 ASN Renal Week 44 System Pharmacists ASHP 44 telcagepant 44 trastuzumab emtansine T DM1 44 Ocrelizumab 44 Gleevec imatinib mesylate 44 ABCSG 44 Hormone Refractory Prostate Cancer 44 Estybon ™ 44 preclinically 44 Angiogenesis 44 Rexin G 44 XL# SAR# 44 forodesine 44 Windhover Therapeutic Area 44 NCCN Clinical Practice 44 TroVax 44 Unither 44 Orazol 44 Genta Incorporated OTCBB GETA 44 AIR2 Trial 44 Infectious Diseases ECCMID 44 RECORD1 44 adecatumumab 44 Immunology ACAAI 44 Chemophase 44 www.aacr.org 44 panobinostat 44 PSMA ADC 44 ALLHAT 44 voreloxin 44 Related Disorders ICAD 44 Xelox 44 multicenter clinical 44 Azedra 44 BrachySil TM 44 AEterna 44 Cell Lung Cancer 44 anastrozole 44 DSMB 44 mCRC 44 Ziopharm 44 Phase III 44 American Roentgen Ray 44 investigational immunotherapy 44 advanced NSCLC 44 malignant pleural mesothelioma 44 LymphoStat B TM 44 NASDAQ SLXP today 44 TASQ 44 Sym# 44 adult chronic ITP 44 Chest Physicians CHEST 44 elacytarabine 44 EGS# 44 Diabetes EASD 44 NSABP C 44 Inc. NASDAQ SGEN 44 TSXV MFS 44 MEND CABG 44 tasocitinib 44 AAGL 44 Annual HIMSS 44 Sapien valve 44 Lorus Therapeutics 44 antiplatelet 44 entecavir 44 RVX 44 PROactive Study 44 Ophthalmology AAO 44 peer reviewed journal Annals 44 alemtuzumab Campath 44 Nephrology ASN 44 Vascular Annual Meeting 44 BIBW 44 histone deacetylase HDAC inhibitor 44 ZYBRESTAT 44 targeting CD# 44 elotuzumab 44 Wound Healing Society 44 Phase 2a 44 ACC AHA 44 randomized Phase IIb 44 Rheumatology ACR 44 Menopause Society 44 Genome Biology 44 relapsed refractory multiple myeloma 44 Movement Disorder 44 NCI 44 SPIRIVA HandiHaler 44 REVLIMID 44 Celsion Corporation 44 Seattle Genetics SGEN 44 ASTMH 44 Atiprimod 44 PROSTVAC ® 44 Adjuvant 44 Advanced Renal Cell 44 Natalizumab 44 bortezomib Velcade 44 antiangiogenic therapy 44 phase IIb study 44 metastatic CRC 44 Interventional Radiology 44 GTCbio 44 Onrigin 44 aclidinium bromide 44 CCX# 44 RECIST Response Evaluation Criteria 44 Poster Presentation 44 Annual BIO 44 Inc. Nasdaq VRUS 44 TARGIT 44 Inc. Nasdaq SGEN 44 Arzerra 44 peer reviewed literature 44 Ixempra 44 Mass Spectrometry ASMS 44 ARVO Annual Meeting 44 pan HDAC inhibitor 44 Antisense 43 hepatocellular cancer 43 Talabostat 43 Integrative Oncology 43 SCCHN 43 Pixuvri 43 Plastic Surgeons ASPS Plastic 43 trastuzumab Herceptin 43 registrational Phase 43 Pertuzumab 43 CIBMTR 43 refractory metastatic 43 Inc. Nasdaq MLNM 43 Gemzar ® 43 Boceprevir 43 Metastatic Melanoma 43 Folotyn 43 Tesetaxel 43 Cloretazine R VNP#M 43 NanoCommerce 43 Group RTOG 43 Votrient 43 NovoTTF 43 Erlotinib 43 Phase 2b 43 Doxil ® 43 Archexin 43 Mr. Kriegsman 43 NABTT 43 ESAs 43 mitogen activated ERK kinase 43 NCCN Guidelines ™ 43 Cystic Fibrosis Conference NACFC 43 PROVENGE 43 REALITY Trial 43 Theratope 43 ProLindac 43 Hexvix 43 ASNR 43 Phase III HEAT 43 Phase III Trials 43 hormone refractory metastatic prostate 43 Antegren 43 Tocosol Paclitaxel 43 huC# DM4 43 Arimidex anastrozole 43 Denufosol 43 Cardiovascular Angiography 43 pain palliation 43 th Annual Interscience 43 sunitinib 43 ILADS 43 metastatic renal cell 43 ONTARGET 43 pemetrexed Alimta 43 Cancer Therapy 43 GTCbio 3rd 43 Photocure ASA 43 Exco InTouch 43 riociguat 43 RP# [002] 43 Recentin 43 Blinatumomab 43 Endoscopic Surgeons SAGES 43 Adaptive Clinical Trials 43 NASDAQ ARRY 43 ISEL 43 MEK inhibitors 43 Clinical Practice Guidelines 43 Pazopanib 43 Phase III TRIST 43 Genentech Avastin 43 ESCRS 43 Neurological Surgeons 43 evaluable patients 43 XL# XL# XL# 43 In3 EUROPE 43 BioPharm America 43 Ceflatonin R 43 Plicera 43 Sorafenib 43 randomized Phase 2b 43 APOPTONE 43 Delcath Phase III 43 Randomized Phase II 43 REG2 43 Infectious Diseases Society 43 Provectus Pharmaceuticals 43 perifosine KRX 43 Epidemiological Studies Unit 43 Endovascular Therapy 43 everolimus 43 proteasome inhibitors 43 GAP #B# 43 including eniluracil ADH 43 Fabry Disease 43 bavituximab 43 ARBITER 6 43 Inc. Nasdaq OPTR 43 romidepsin 43 pharmacokinetic PK 43 Medicine AAPM 43 Benlysta 43 EGFR HER2 43 VEITHsymposium ™ 43 refractory multiple myeloma 43 Windhover Information 43 Nasdaq OPTR 43 HIF PHI 43 ISTODAX ® 43 immatics 43 brentuximab vedotin SGN 43 rALLy clinical trial 43 Colposcopy 43 DAVANAT 43 compound AEZS 43 PIX# [002] 43 Venereology EADV 43 AMCP 43 PROLARIS 43 atacicept 43 Deforolimus 43 Certican 43 ARRY 43 Immunogen 43 Xanafide 43 clinical 43 TroVax ®